You are here

Encision Reports Fourth Quarter Fiscal Year 2019 Results

BOULDER, Colo., May 14, 2019 /PRNewswire/ -- Encision Inc. (PK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2019 fourth quarter that ended March 31, 2019.

The Company posted quarterly net revenue of $2.09 million for a quarterly net loss of $183 thousand, or $(0.02) per diluted share. These results compare to net revenue of $2.04 million for a quarterly net loss of $18 thousand, or $0.00 per diluted share, in the year-ago quarter. Net revenue for last year's quarter included net revenue of $68.3 thousand from an order for non-AEM product. Gross margin on net revenue was 53% in the fiscal 2019 fourth quarter and 57% in the fiscal 2018 fourth quarter. Gross margin on net revenue was lower in the current quarter primarily as a result of significantly higher material costs, especially as a result of tariffs on our steel costs and, to a lesser extent, product mix.

The Company posted twelve months net revenue of $8.80 million for a twelve months net loss of $236 thousand, or $(0.02) per diluted share. These results compare to net revenue of $8.75 million for a twelve months net income of $336 thousand, or $0.03 per diluted share, in the year-ago twelve months. Net revenue for last year's twelve months included net revenue of $492 thousand from an order for non-AEM product. Gross margin on net revenue was 53% in the fiscal 2019 twelve months and 57% in the fiscal 2018 twelve months. Gross margin on net revenue was lower in the current twelve months as a result of higher material costs and product mix.

"Core AEM® Technology sales are increasing.  For this fiscal year's twelve months, net revenue on AEM products resulted in a 7% rate of growth," said Gregory Trudel, President and CEO of Encision Inc.  "We continue to open up new market opportunities.  During the quarter ended March 31, 2019, our proprietary patient safety technology was recognized by the U.S. Department of Veterans Affairs and provides us with the opportunity to market our instruments and monitors into VA Medical Centers. The VA is the largest medical system in the U.S. providing service to more than nine million veterans across more than 1,200 facilities.  Also, during the quarter, Encision was awarded a prestigious Vizient Innovative Technology Contract for monopolar surgical instruments and monitors. This contract will enable us to expand the use of our technology and to provide savings opportunities into thousands of new hospital accounts. Vizient represents a diverse membership base that includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers and represents approximately $100 billion in annual purchasing volume.  We appreciate the VA's and Vizient's recognition and look forward to driving top line growth in FY2020."

Encision Inc. designs and markets a portfolio of high performance surgical instrumentation that delivers advances in patient safety with AEM technology, surgical performance, and value to hospitals across a broad range of minimally invasive surgical procedures. Based in Boulder, Colorado, the company pioneered the development and deployment of Active Electrode Monitoring, AEM technology, to eliminate dangerous stray energy burns during minimally invasive procedures. For additional information about all our products, please visit www.encision.com.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to develop new or enhanced products and have such products accepted in the market, its ability to increase net sales through the Company's distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company's Annual Report on Form 10-K for the year ended March 31, 2018 and subsequent filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.

CONTACT:  Mala Ray, Encision Inc., 303-444-2600, mray@encision.com

Encision Inc.

Unaudited Condensed Statements of Operations

(in thousands, except per share information)



Three Months Ended

Years Ended


March 31, 2019


March 31, 2018


March 31, 2019


March 31, 2018

Net revenue

$2,085


$2,038


$8,803


$8,754

Cost of revenue

982


867


4,131


3,747

Gross profit

1,103


1,171


4,672


5,007

Operating expenses:








    Sales and marketing

686


567


2,763


2,312

    General and administrative

361


399


1,315


1,457

    Research and development

237


207


780


842

        Total operating expenses

1,284


1,173


4,858


4,611

Operating income (loss)

(181)


(2)


(186)


396

Interest expense and other expense, net

––


(16)


(50)


(60)

Income (loss) before provision for income taxes

(2)


(18)


(236)


336

Provision for income taxes

––


––


––


––

Net income (loss)

$ (183)


$ (18)


$ (236)


$ 336

Net income (loss) per share—basic and diluted

$(0.02)


$0.00


$(0.02)


$0.03

Weighted average number of shares— basic

11,558


10,683


10,933


10,683

Weighted average number of shares—  diluted

11,558


10,683


10,933


10,707

 

Encision Inc.

Unaudited Condensed Balance Sheets

(in thousands)




March 31, 2019


March 31, 2018

ASSETS





Cash and cash equivalents


$     273


$    115

Restricted cash


25


25

Accounts receivable, net


1,009


962

Inventories, net


1,473


1,437

Prepaid expenses


130


75

    Total current assets


2,910


2,614

Equipment, net


250


349

Patents, net


249


270

Other assets


19


19

    Total assets


$ 3,428


$ 3,252

LIABILITIES AND SHAREHOLDERS' EQUITY





Accounts payable


$   579


$   466

Accrued compensation


296


257

Other accrued liabilities


126


285

Deferred rent


10


30

    Total current liabilities


1,011


1,038

Deferred rent


65


10

    Total liabilities


1,076


1,048

Common stock and additional paid-in capital


24,202


23,818

Accumulated (deficit)


(21,850)


(21,614)

    Total shareholders' equity


2,352


2,204

    Total liabilities and shareholders' equity


$ 3,428


$ 3,252

 

Encision Inc.

Unaudited Condensed Statements of Cash Flows

(in thousands)



Years Ended


March 31, 2019


March 31, 2018

Operating activities:




    Net income (loss)

$ (236)


$  336

    Adjustments to reconcile net income (loss) to cash generated by operating activities:




    Depreciation and amortization

182


203

    Share-based compensation expense

37


66

    (Recovery from) provision for doubtful accounts, net

6


(13)

    (Recovery from) inventory obsolescence, net

29


(29)

    Changes in operating assets and liabilities:




        Accounts receivable     

(52)


92

        Inventories

(64)


(280)

        Prepaid expenses and other assets

(56)


(15)

        Accounts payable

111


64

        Accrued compensation and other accrued liabilities

(85)


(4)

            Net cash generated by operating activities

(128)


420





Investing activities:




    Acquisition of property and equipment

(55)


(57)

    Patent costs

(6)


(43)

            Net cash (used in) investing activities

(61)


(100)





Financing activities:




    Paydown of credit facility, net change

––


(275)

    Net  proceeds from the issuance of common stock

347


25

            Net cash generated by (used in) financing activities

347


(250)





Net increase in cash, cash equivalents and restricted cash

158


70

Cash, cash equivalents and restricted cash, beginning of period

140


45

Cash, cash equivalents and restricted cash, end of period

$    298


$ 115

 

Cision View original content:http://www.prnewswire.com/news-releases/encision-reports-fourth-quarter-fiscal-year-2019-results-300849349.html

SOURCE Encision Inc.